• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Omega Alpha SPAC

    1/6/23 6:11:33 AM ET
    $OMEG
    Business Services
    Finance
    Get the next $OMEG alert in real time by email
    15-12G 1 tm231691d1_1512g.htm FORM 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 15

     

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF
    THE SECURITIES EXCHANGE ACT OF 1934.

     

    001-39840

    Commission File Number

     

     

     

    OMEGA ALPHA SPAC

    (Exact name of registrant as specified in its charter)

     

     

     

    888 Boylston Street, Suite 1111

    Boston, MA 02199

    (857) 268-4429

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Class A ordinary shares, $0.0001 par value per share

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1) x
    Rule 12g-4(a)(2) ¨
    Rule 12h-3(b)(1)(i) x
    Rule 12h-3(b)(1)(ii) ¨
    Rule 15d-6 ¨
    Rule 15d-22(b) ¨

     

    Class A ordinary shares, $0.0001 par value per share: 0 holders

     

     

     

     

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

    Pursuant to the requirements of the Securities Exchange Act of 1934, Omega Alpha SPAC has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

     

    Date:  January 6, 2023 By:  /s/ Otello Stampacchia
        Name: Otello Stampacchia
        Title: Chief Executive Officer

     

     

     

    Get the next $OMEG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMEG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OMEG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies

    BOSTON, Dec. 17, 2021 /PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million in limited partner capital commitments. The new fund, Omega Fund VII, L.P. ("Fund VII"), was oversubscribed, exceeding the firm's targeted raise of $500 million, and included strong support from both new and existing limited partners. With Fund VII, the firm will continue to execute on its strategy of creating and investing in life sciences companies in the US and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has r

    12/17/21 8:00:00 AM ET
    $ADGI
    $ICVX
    $IKNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Business Services

    $OMEG
    SEC Filings

    View All

    SEC Form 15-12G filed by Omega Alpha SPAC

    15-12G - Omega Alpha SPAC (0001832010) (Filer)

    1/6/23 6:11:33 AM ET
    $OMEG
    Business Services
    Finance

    SEC Form 25-NSE filed by Omega Alpha SPAC

    25-NSE - Omega Alpha SPAC (0001832010) (Subject)

    12/27/22 4:15:27 PM ET
    $OMEG
    Business Services
    Finance

    Omega Alpha SPAC filed SEC Form 8-K: Other Events

    8-K - Omega Alpha SPAC (0001832010) (Filer)

    12/23/22 4:05:26 PM ET
    $OMEG
    Business Services
    Finance

    $OMEG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Omega Alpha SPAC (Amendment)

    SC 13G/A - Omega Alpha SPAC (0001832010) (Subject)

    2/14/23 2:16:43 PM ET
    $OMEG
    Business Services
    Finance

    SEC Form SC 13G/A filed by Omega Alpha SPAC (Amendment)

    SC 13G/A - Omega Alpha SPAC (0001832010) (Subject)

    2/14/23 7:41:31 AM ET
    $OMEG
    Business Services
    Finance

    SEC Form SC 13G/A filed by Omega Alpha SPAC (Amendment)

    SC 13G/A - Omega Alpha SPAC (0001832010) (Subject)

    2/9/23 11:07:54 AM ET
    $OMEG
    Business Services
    Finance